Scandion Oncology (OMX: SCOL)

Currency in SEK

Last close As at 06/02/2023

SEK2.94

−0.09 (−2.97%)

Market capitalisation

SEK124m

Scandion Oncology is focused on the development of add-on therapies to reverse chemotherapy resistance in oncology. Lead asset SCO-101 is in a Phase II trial for mCRC and a Phase Ib trial for pancreatic cancer.

Tumours often develop resistance to chemotherapeutic regimens. Widely available drugs, such as irinotecan and paclitaxel, are commonly associated with tumour resistance. The existence of add-on therapies to reverse resistance of this type will be an attractive prospect to many clinicians, in our view.

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Johnny Stilou

    CFO

  • Mads Kronborg

    Head of external communication

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.1 37.0 (82.8)
Relative (4.1) 16.6 (81.5)
52 week high/low SEK17.6/SEK1.9

Financials

Scandion Oncology is a biotechnology company focused on the development of add-on therapies to reverse chemotherapy resistance in oncology. The company’s lead asset SCO-101 is currently in a Phase II trial for metastatic colorectal cancer (mCRC) and a Phase Ib trial for pancreatic cancer. In H222 management undertook a rights issue, raising c SEK75m gross, mainly to fund the expansion of the SCO-101 clinical development programme to include patients harbouring RAS mutations. As such, part 3 of the CORIST trial in mCRC began enrolment in October 2022. While top-line readouts from the CORIST part 2 mCRC trial did not achieve the primary endpoint for efficacy, patients are continuing treatment and longer-term efficacy benefits may be realised. We estimate that the company is funded into FY24. We value Scandion Oncology at SEK241.1m or SEK5.9/share.

Y/E Dec Revenue (DKKm) EBITDA (DKKm) PBT (DKKm) EPS (ore) P/E (x) P/CF (x)
2020A 1.0 (23.5) (21.5) (53.0) N/A N/A
2021A 0.8 (54.8) (57.2) (161.0) N/A N/A
2022E 0.6 (85.1) (87.7) (225.0) N/A N/A
2023E 0.6 (76.0) (75.8) (173.0) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free